Adjunctive risperidone, olanzapine and quetiapine for the treatment of hospitalized patients with bipolar I disorder: A retrospective study

Chi Un Pae; S. Nassir Ghaemi; Ashwin Patkar; Jeong Ho Chae; Won Myong Bahk; Tae Youn Jun; Prakash Masand

doi:10.1016/j.pnpbp.2006.03.020

Adjunctive risperidone, olanzapine and quetiapine for the treatment of hospitalized patients with bipolar I disorder: A retrospective study

Chi Un Pae
, S. Nassir Ghaemi
, Ashwin Patkar
, Jeong Ho Chae
, Won Myong Bahk
, Tae Youn Jun
, Prakash Masand

Department of Psychiatry

Emory University
Duke University
Catholic Univ. of Korea Coll. Med.

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

This study evaluated the overall effectiveness and tolerability of atypical antipsychotics (risperidone vs. olanzapine vs. quetiapine) used in the treatment of bipolar inpatients. After screening 463 patients, the medical records of 158 inpatients with bipolar I disorder, who were given olanzapine, risperidone or quetiapine as adjuncts to mood stabilizers for at least 1 month and not administered with any other antipsychotics, were examined. Details of the tolerability and effectiveness were reviewed according to the treatment records during their hospital stay. The results showed equivalent effectiveness based on the Clinical Global Impression (CGI) and Global Assessment Functioning (GAF) score between the three atypical antipsychotics. The frequency of the extrapyramidal symptom-related side effects were higher in the risperidone-treated group than in the olanzapine and quetiapine-treated group. This suggests that risperidone, olanzapine and quetiapine have a comparable effectiveness in inpatients with bipolar I disorder in a naturalistic setting. However, there were some differences in tolerability between these results as reported from previous Western studies.

Original language	English
Pages (from-to)	1322-1325
Number of pages	4
Journal	Progress in Neuro-Psychopharmacology and Biological Psychiatry
Volume	30
Issue number	7
DOIs	https://doi.org/10.1016/j.pnpbp.2006.03.020
State	Published - 30 Sep 2006

Keywords

Bipolar I disorder
Inpatients
Naturalistic study
Olanzapine
Quetiapine
Risperidone

Access to Document

10.1016/j.pnpbp.2006.03.020

Cite this

@article{363e61750f41437c92245ff62ce6ed2a,

title = "Adjunctive risperidone, olanzapine and quetiapine for the treatment of hospitalized patients with bipolar I disorder: A retrospective study",

abstract = "This study evaluated the overall effectiveness and tolerability of atypical antipsychotics (risperidone vs. olanzapine vs. quetiapine) used in the treatment of bipolar inpatients. After screening 463 patients, the medical records of 158 inpatients with bipolar I disorder, who were given olanzapine, risperidone or quetiapine as adjuncts to mood stabilizers for at least 1 month and not administered with any other antipsychotics, were examined. Details of the tolerability and effectiveness were reviewed according to the treatment records during their hospital stay. The results showed equivalent effectiveness based on the Clinical Global Impression (CGI) and Global Assessment Functioning (GAF) score between the three atypical antipsychotics. The frequency of the extrapyramidal symptom-related side effects were higher in the risperidone-treated group than in the olanzapine and quetiapine-treated group. This suggests that risperidone, olanzapine and quetiapine have a comparable effectiveness in inpatients with bipolar I disorder in a naturalistic setting. However, there were some differences in tolerability between these results as reported from previous Western studies.",

keywords = "Bipolar I disorder, Inpatients, Naturalistic study, Olanzapine, Quetiapine, Risperidone",

author = "Pae, \{Chi Un\} and \{Nassir Ghaemi\}, S. and Ashwin Patkar and Chae, \{Jeong Ho\} and Bahk, \{Won Myong\} and Jun, \{Tae Youn\} and Prakash Masand",

year = "2006",

month = sep,

day = "30",

doi = "10.1016/j.pnpbp.2006.03.020",

language = "English",

volume = "30",

pages = "1322--1325",

journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",

issn = "0278-5846",

publisher = "Elsevier Inc.",

number = "7",

}

Adjunctive risperidone, olanzapine and quetiapine for the treatment of hospitalized patients with bipolar I disorder: A retrospective study. / Pae, Chi Un; Nassir Ghaemi, S.; Patkar, Ashwin et al.
In: Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 30, No. 7, 30.09.2006, p. 1322-1325.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Adjunctive risperidone, olanzapine and quetiapine for the treatment of hospitalized patients with bipolar I disorder

T2 - A retrospective study

AU - Pae, Chi Un

AU - Nassir Ghaemi, S.

AU - Patkar, Ashwin

AU - Chae, Jeong Ho

AU - Bahk, Won Myong

AU - Jun, Tae Youn

AU - Masand, Prakash

PY - 2006/9/30

Y1 - 2006/9/30

N2 - This study evaluated the overall effectiveness and tolerability of atypical antipsychotics (risperidone vs. olanzapine vs. quetiapine) used in the treatment of bipolar inpatients. After screening 463 patients, the medical records of 158 inpatients with bipolar I disorder, who were given olanzapine, risperidone or quetiapine as adjuncts to mood stabilizers for at least 1 month and not administered with any other antipsychotics, were examined. Details of the tolerability and effectiveness were reviewed according to the treatment records during their hospital stay. The results showed equivalent effectiveness based on the Clinical Global Impression (CGI) and Global Assessment Functioning (GAF) score between the three atypical antipsychotics. The frequency of the extrapyramidal symptom-related side effects were higher in the risperidone-treated group than in the olanzapine and quetiapine-treated group. This suggests that risperidone, olanzapine and quetiapine have a comparable effectiveness in inpatients with bipolar I disorder in a naturalistic setting. However, there were some differences in tolerability between these results as reported from previous Western studies.

AB - This study evaluated the overall effectiveness and tolerability of atypical antipsychotics (risperidone vs. olanzapine vs. quetiapine) used in the treatment of bipolar inpatients. After screening 463 patients, the medical records of 158 inpatients with bipolar I disorder, who were given olanzapine, risperidone or quetiapine as adjuncts to mood stabilizers for at least 1 month and not administered with any other antipsychotics, were examined. Details of the tolerability and effectiveness were reviewed according to the treatment records during their hospital stay. The results showed equivalent effectiveness based on the Clinical Global Impression (CGI) and Global Assessment Functioning (GAF) score between the three atypical antipsychotics. The frequency of the extrapyramidal symptom-related side effects were higher in the risperidone-treated group than in the olanzapine and quetiapine-treated group. This suggests that risperidone, olanzapine and quetiapine have a comparable effectiveness in inpatients with bipolar I disorder in a naturalistic setting. However, there were some differences in tolerability between these results as reported from previous Western studies.

KW - Bipolar I disorder

KW - Inpatients

KW - Naturalistic study

KW - Olanzapine

KW - Quetiapine

KW - Risperidone

UR - https://www.scopus.com/pages/publications/33747079497

U2 - 10.1016/j.pnpbp.2006.03.020

DO - 10.1016/j.pnpbp.2006.03.020

M3 - Article

C2 - 16631294

AN - SCOPUS:33747079497

SN - 0278-5846

VL - 30

SP - 1322

EP - 1325

JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry

IS - 7

ER -

Adjunctive risperidone, olanzapine and quetiapine for the treatment of hospitalized patients with bipolar I disorder: A retrospective study

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this